A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis

Silvia Moretti(University of Perugia), Giorgia Renga(University of Perugia), Vasileios Oikonomou(University of Perugia), Claudia Galosi(University of Perugia), Marilena Pariano(University of Perugia), Rossana G. Iannitti(University of Perugia), Monica Borghi(University of Perugia), Matteo Puccetti(University of Perugia), Marco De Zuani(University of Udine), Carlo Pucillo(University of Udine), Giuseppe Paolicelli(University of Perugia), Teresa Zelante(University of Perugia), Jean‐Christophe Renauld(Ludwig Cancer Research), Oxana Bereshchenko(University of Perugia), Paolo Sportoletti(Ospedale Santa Maria), V. Lucidi(Bambino Gesù Children's Hospital), Maria Chiara Russo(University of Milan), Carla Colombo(University of Milan), Ersilia Fiscarelli(Bambino Gesù Children's Hospital), Cornelia Lass‐Flörl(Innsbruck Medical University), Fabio Majo(Bambino Gesù Children's Hospital), Gabriella Ricciotti(Bambino Gesù Children's Hospital), Helmut Ellemunter(Innsbruck Medical University), Luigi Ratclif(Presidio Ospedaliero), Vincenzo Nicola Talesa(University of Perugia), Valerio Napolioni(University of Perugia), Luigina Romani(University of Perugia)
Nature Communications
January 16, 2017
Cited by 128Open Access
Full Text

Abstract

Abstract T helper 9 (Th9) cells contribute to lung inflammation and allergy as sources of interleukin-9 (IL-9). However, the mechanisms by which IL-9/Th9 mediate immunopathology in the lung are unknown. Here we report an IL-9-driven positive feedback loop that reinforces allergic inflammation. We show that IL-9 increases IL-2 production by mast cells, which leads to expansion of CD25 + type 2 innate lymphoid cells (ILC2) and subsequent activation of Th9 cells. Blocking IL-9 or inhibiting CD117 (c-Kit) signalling counteracts the pathogenic effect of the described IL-9-mast cell-IL-2 signalling axis. Overproduction of IL-9 is observed in expectorates from cystic fibrosis (CF) patients, and a sex-specific variant of IL-9 is predictive of allergic reactions in female patients. Our results suggest that blocking IL-9 may be a therapeutic strategy to ameliorate inflammation associated with microbial colonization in the lung, and offers a plausible explanation for gender differences in clinical outcomes of patients with CF.


Related Papers

No related papers found

Powered by citation graph analysis